Showing posts with label Hyperuricemia. Show all posts
Showing posts with label Hyperuricemia. Show all posts

Friday, July 3, 2020

D-0120, a Novel Oral Selective Uric Acid Transporter Inhibitor, at the 2020 EULAR Online Meeting


It seems that we never have enough different drugs to lower hyperuricemia for the individual patient. Lesinurad is an oral selective uric acid transporter (URAT1) inhibitor, which has both FDA (2015) and EMA (2016) approval and is on the market under the brand name of Zurampic, but isn't sold in Germany for instance [1]. Now comes D-0120, a novel oral selective uric acid transporter (URAT1) inhibitor with one study at the 2020 EULAR Online Meeting. Will there be a market for such a drug?

L. Zhang presented the following study [2]: „OP0205 PHASE I STUDY OF D-0120, A NOVEL URAT1 INHIBITOR IN CLINICAL DEVELOPMENT FOR HYPERURICEMIA AND GOUT“. Daily oral D-0120, at dose levels from 2.5 mg/day to 20 mg/day in 32 healthy volunteers for 7 days was well tolerated. The pharmacokinetics profile demonstrated a dose proportional increase. There had been a significant reduction of serum uric acid levels.

Will there be a market for D-0120? D-0120 showed in a cell model a 150-fold more potent inhibitory activity than lesinurad, which might result in less side effects (hope and speculation!). This might be the pivotal point to go on studying D-0120. There will be patients needing an oral selective uric acid transporter (URAT1) inhibitor, but will there be enough patients to support the another drug of the kind that we already have?

Nevertheless I hope that studies go on and that D-0120 will come to market. That will take some years. In the mean time lesinurad should be available on the German market.


Links and References:
[2] L. Zhang1, D. Wyatt2, K. Stazzone1, Z. Shi1, Y. Wang1. OP0205 PHASE I STUDY OF D-0120, A NOVEL URAT1 INHIBITOR IN CLINICAL DEVELOPMENT FOR HYPERURICEMIA AND GOUT. DOI: 10.1136/annrheumdis-2020-eular.5107

.




Monday, July 15, 2013

Gout at the EULAR 2013 Meeting in Madrid


There were far too many posters, talks, abstracts, etc. at the EULAR 2013 Meeting in Madrid than to comment on everything. So I select my personal highlights and updates.

B. Manger [SP0006] talked on “Visualising crystals: DECT and more”. “Dual energy computed tomography (DECT) is an imaging method, which uses X-ray beams of two different energies to differentiate solid sodium urate deposits from connective tissues and from calcium containing structures by their absorption properties.” “…,DECT may not only be a very helpful imaging method for tophus assessment and follow-up in clinical trials and during urate lowering therapy in patients with the established diagnosis of chronic gout. It may also be valuable as differential diagnostic tool in patients with “unclassified” acute or relapsing arthritides, when aspiration of synovial fluid is not possible or not successful.“
I haven’t used DECT yet and also don’t know, where to look for someone, who is experienced in this method, here in the vicinity.

S.-J. Kee and colleagues studied [OP0002]: “Pathomechanism of bone destruction in chronic gouty arthritis”. “MSU [monosodium urate monohydrate] crystals induced the expressions of IL-1, IL-6, TNF-alpha and RANKL in PBMCs [peripheral blood mononuclear cells], but inhibited OPG [osteoprotegerin] expression.” Conclusions: “ …, our data show that MSU crystals have the potential to induce pro-resorptive cytokines, and T cells are involved in osteoclastogenesis in chronic gout.” Good basic research, which might lead to understand, why erosive lesions look different in gout and RA for instance.

T. Cooper and colleagues presented a study [FRI0568-PC]: “Gout: are we getting it right in primary care? An audit of serum uric acid level measurement and monitoring.” Methods: “This study audited one general practice in the UK.” Results: “A total of 125 patients had received allopurinol in the 3 year period. 76 patients (60.8%) had not had their SUA level measured, leaving only 49 (39.2%) who had their SUA levels checked. …”. Conclusions: “Clearly the majority of patients receiving allopurinol in this general practice were not having their SUA levels measured, being treated to target or monitored annually. If these simple tests and management strategies were performed in primary care then a large number of hospital admissions for attacks of gout could be avoided, with the accompanying save in expenditure. …”
So, it’s important to have revisits by the patient, who have been presented to rheumatologists in order to help our colleagues in primary care, once we’ve seen these gout patients as I presume they suffer from more severe or complicated forms of gout.

D. Chandrasekaran and colleagues presented [SAT0363]: “Evaluation of the use of colchicine in the management of chronic gout.” The authors looked at 515 patients taking colchicines. Conclusions: “… a significant percentage of gout patients are inappropriately on long-term colchicine with only 26% having serum uric acid levels at or below the target level of 6 mg/dl.”
I may add that some GPs don’t read the letters, maybe because the patients don’t show up or maybe because they think that the gout problem has been solved, once the arthritis has been treated. With us rheumatologists there rests an educational responsibility – we have to both educate our referring colleagues as well as our gout patients, whom we normally see only sporadically.  

D. Khanna and colleagues looked at [SAT0384]: “Patients that continue to flare despite reaching EULAR/ ACR recommended serum urate target.” Conclusions: “Less than 50% of patients treated with a XOI inhibitor alone reached sUA target. Of the patients achieving a sUA level of < 6 mg/dL, over a third reported 2 or more flares in a 12-month period.”
Can you see gout patients, who do not flare? I can’t as our outpatient department is only allowed to see patients suffering from severe auto inflammatory diseases. How can we help then? Wait till the poor patients flares again? I don’t have an easy answer.

Gout is a topic that lots of colleagues outside the rheumatologic world feel fit in, but there are still gaps to be filled. I read out of the above studies, that we as rheumatologists have an educational responsibility owards colleagues in primary care and patients as well.


More on gout:
Gout / subcutaneous depots of uric acid http://twitpic.com/4q61mh

Monday, May 14, 2012

Some Ideas on Gout



As I was taking part in the 3e National Expert Meeting on gout, I´ve prepared myself for the talks and sub meetings with rereading old material and looking for some new research on gout. 3e stands for evidence, experts, exchange. The topics have been diagnosis and management of gout. The following text is by no way a summary of the 3e meeting – after the national meetings have been conducted, the iniative meets on international level and after that meeting we shall see the final results on gout, and these results will be published by 3e.
The 3e meeting has been a good stimulus for me to put together some of the material I had collected over the past years and of which I already had published some here on this blog or on twitpic:
An expedition into the world of gout http://rheumatologe.blogspot.de/2012/04/expedition-into-world-of-gout_27.html
Tophi http://twitpic.com/4q61mh
Hyperuricemia and Gout ACR2011 http://rheumatologe.blogspot.com/2011/11/hyperuricemia-and-gout.html

Gout is a systemic disease
New research found that gout dos not only affect joint. Uric acid may be found even in the eyes. Most prominent and known for a long time are the deposits under the skin, the tophi. I have already shown a very drastic example on twicpic. Uric acid has been found in the pancreas, which may sound exotic, but as no one has researched the question of deposits of uric acid in the different tissues of inner organs systemically, it might turn out that this is a frequent finding with people suffering from hyperuricemia. One can find these deposits with a newly developed technique in CT, the dual energy CT.
Cardiovascular mortality rises 9% in men and 26% in woman with each increase by 1 mg/ml of uric acid level in a study of 6000 people over 16 years.
Reducing elevated uric acid leads to a reduction of hypertension.
High uric acid levels are also associated with a high incidence of kidney failure as shown in an Austrian study with 21.000 healthy people.
High uric acid levels seem to promote osteoarthritis.


Interleukin 1ß
Interleukin 1ß plays a role in gouty inflammation in activating the inflammasom complex. Therefore IL-1-inhibitors try to get approval for gout. On May the 8th 2012 FDA's Arthritis Advisory Committee voted 11-0 against approval of rilonacept (Arcalyst) to prevent gout flares in adults initiating uric acid-lowering therapy. Rilonacept showed a treatment effect to prevent gout flares in adults initiating uric acid-lowering therapy (0.3 flares vs.1.0 flares in the placebo group), but was also associated with an increased risk of malignancy (6 in the verum group and none in the placebo group!). It's more than debatable if 16-week safety studies are adequate to say anything on long term safety.
Canakinumab has been tested in different dosages for the same purpose, but it is unclear why one should use such a high risk and tigh end cost therapy other than to make the pharmaceutical firm happy.


Reducing elevated uric acid levels after a gout attack
Why start reducing high, even very high uric acid levels right with the gout attack? Lots of GPs do, but there is no good reason behind this strategy. Uric acid has accumulated during years, if you abruptly reduce the blood level of uric acid you might induce repeated gout attacks. First control the attack and then slowly and continuously reduce the elevated uric acid level. Even starting with low dose allopurinol warrants a low dose colchicine therapy to prevent a gout attack in the wake of normalizing uric acid levels. The cartilage has a slow metabolism and stores uric acid which could be released into the joint space and fall out as crystals there.




Hyperuricemia and diet
Gout is a disease of hyperalimentation and a diet being rich in purines. Your diet might overload the body with purines or reduce the capacity to eliminate them.
A very high risk is associated with alcohol, which reduces elimination, that means vodka, whiskey, brandy etc., but also beer as it contains purines from the yeast. Wine is exonerated, in little quantities. Most people know that meat, red meat, organ meats, fish and shellfish increase uric acid levels. Another risk factor is high intake of fructose, which is used to to sweeten soft drinks, and also fruits juices and fruits high in fructose might add. There migh be niche for diet drinks (artificial sweeteners) after all. Asparagus and other vegetables containing containing purines don't increase the risk of gout attacks.
Reduction of uric acid levels: low fat milk products, coffee (to a lesser degree decaffinated coffee, but not tea), vitamin C. [source Medical Tribune, Germany]



Monday, November 14, 2011

Hyperuricemia and Gout

Gout follows hyperuricemia, which follows overindulging in food and drinks. On twitter you would block and report such fellows! The incidence of gout has risen during the last decades (Arromdee et al. have shown the incidence to double from the 70ies to the 90ies; Zhu et al. have shown an increase of up to 114% in certain subgroups in the US).
Marc Pillinger, MD, who is Associate Professor of Medicine and Pharmacology at the NYU Langone Medical Center, gave an interesting talk on gout at the 2011 ACR Scientific Meeting in Chicago. He asked about the factors, why gou and hyperuricemia are increasing in the population. People live longer, there are more people with kidney disease, diuretics are used more often, diet patterns have changed, and obesityhas become epidemic. Gout is expensive and gout patients habour lots of co-morbidities as hypertension, hyperlipidemia, chronic kidney disease, diabetes, coronary artery disease. Studies indicate, that lowering uric acid in these patients might reverse these co-morbidities (hypertension, hyperlipidemia, chronic kidney disease, diabetes, coronary artery disease) – lots of research work still to be done though! Some studies found an increased prevalence and severity of osteoarthritis.
Old treatment options are reducing inflammation by NSAIDs, colchicine, corticosteroids, and lowering uric acid by allopurinol, benzbromarone, probenecid. New treatment options are reducing inflammation by anakinra (Il-1 receptor antagonist), rilonacept (Il-1 trap), canakimumab (Anti-Il-1 Ig), and lowering uric acid by febuxostat, pegloticase (pegylated uricase), lesinurad. Pegloticase is highly effective to reduce urid acid, and reduces tophi.

Some foods promote gout as purines in meat and seafood, but also alcoholic beverages, fructose, and more.
Beer is the worst alcoholic beverage to promote hyperuricemia and gout. A really large study (more than 47,000 men) conducted at the Massachusetts General Hospital by Dr. Hyon Choi and her colleagues showed, that consumers of two to four beers a week had a risk increase of 25%, consuming at least 2 beers a day results in a risk increase of 200% of developing gout. Though alcohol itself increases the risk, it is the amount of purines found in beer, that make it worse than the other alcoholic beverages. High-fructose corn syrup (HFCS) results in high uric acid formation, and should therefore be avoided (there are other serious health concerns such as cardiovascular disease, diabetes, and fatty liver disease).


Let’s have a look at some excerpts from abstracts from the 2011 ACR Scientific Meeting in Chicago:


[223] Gout Vs Hyperuricemia As Risk Factors for Coronary Artery Disease – A Pilot Study.
Victoria Furer, Rennie N. G. Howard, Jonathan Samuels and Michael H. Pillinger.
NYU Hospital for Joint Diseases, New York, NY
Conclusion: This well-characterized, prospectively-enrolled cohort study suggests that the presence of gout conveys an additional level of CAD risk beyond that of hyperuricemia. Although larger studies are needed, our pilot study demonstrates the feasibility of using a prospective enrollment strategy to distinguish between hyperuricemia and gout comorbidity.

[1013] Rilonacept for Gout Flare Prevention in Patients on Uric Acid-Lowering Therapy: Results of a Double-Blind, Placebo-Controlled, Phase 3, International Safety Study.

John S. Sundy1, H. Ralph Schumacher2, Judith Kirstein3, Essack Mitha4, Steven P. Weinstein5, Jian Wang5, Shirletta King-Davis5 and Robert R. Evans5.
1Duke University Medical Center, Durham, NC, 2VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3Advanced Clinical Research, West Jordan, UT, 4Newtown Clinical Research, Johannesburg, Gauteng, South Africa, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Conclusion: Rilonacept demonstrated an acceptable safety and tolerability profile in gout patients with typical comorbid conditions. The rate of serious infections was low. Rilonacept resulted in a substantial reduction in gout flares in patients at high risk of flaring.

[1014] Rilonacept Efficacy for Gout Flare Prevention in Patients with Tophi and/or Polyarticular Disease Who Initiate Uric Acid-Lowering Therapy.

Robert Terkeltaub1, H. Ralph Schumacher2, A. Kivitz3, Steven P. Weinstein4, Richard Wu4, Rebecca Gall4 and Robert R. Evans4.
1VA Medical Ctr, San Diego, CA, 2VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3Altoona Center for Clinical Research, Duncansville, PA, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Conclusion: The presence of tophi and/or polyarticular disease represents a risk factor for gout flares in patients initiating uric acid-lowering therapy. Among patients with these risk factors, rilonacept demonstrated efficacy for gout flare prevention that was generally similar to that observed for the overall population.

[1016] Long-Term Efficacy and Safety of Canakinumab Versus Triamcinolone Acetonide in Acute Gouty Arthritis Patients.

J.P. Brown1, A. So2, A. Dikranian3, R. Alten4, T. Bardin5, H. R. Schumacher6, A. Gimona7, G. Krammer7, A. Karpov7 and N. Schlesinger8.
1CHUQ-CHUL Research Centre, Laval University, Quebec City, QC, 2CHUV, Lausanne, Switzerland, 3San Diego Arthritis Medical Clinic, San Diego, CA, 4Charite´ Teaching Hospital–Schlosspark-Klinik, Berlin, Germany, 5Hoˆpital Lariboisie`re, Paris, France, 6University of Pennsylvania and VA Medical Center, Philadelphia, PA, 7Novartis Pharma AG, Basel, Switzerland, 8UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Conclusion: In frequently flaring patients with limited treatment options, canakinumab demonstrated superior 24 week efficacy against TA with comparable safety and tolerability to 12-week data.

[1021] Efficacy and Safety of Lesinurad (RDEA594), A Novel Uricosuric Agent, Given In Combination with Allopurinol in Allopurinol-Refractory Gout Patients: Preliminary Results from the Randomized, Double-Blind, Placebo-Controlled, Phase 2B Extension Study.

John Sundy1, Fernando Perez-Ruiz2, Eswar Krishnan3, Vijay Hingorani4, Jody Welp4, Matt Suster4, Kimberly Manhard4, Matt Cravets4, David Hagerty4 and Barry Quart4.
1Duke University Medical Center, Durham, NC, 2Hospital De Cruces, Baracaldo, Spain, 3Stanford University, Stanford, CA, 4Ardea Biosciences, Inc., San Diego, CA
Conclusion: Addition of lesinurad produced consistent, sustained reductions in sUA levels in patients not adequately responding to standard doses of ALLO. Most subjects achieved target sUA levels of _6 mg/dL on either the 200 or 400mg lesinurad dose. Lesinurad was well-tolerated and no dose-related side effects were observed with combination treatment. Lesinurad is a promising investigational drug for the treatment of hyperuricemia in gout
patients.

[1022] Febuxostat (vs. Allopurinol) In Treating the Hyperuricemia of Gout In Diabetic Patients.

Michael A. Becker1, Patricia A. MacDonald2, Barbara Hunt2 and Robert L. Jackson2.
1University of Chicago Medical Center, Chicago, IL, 2Takeda Global Research & Development Center, Inc., Deerfield, IL
Conclusion: Despite very high rates of CV, renal, and additional metabolic co-morbidities, diabetic gouty subjects tolerated UL therapy with either FEB or ALLO, but FEB 80mg treatment achieved sUA _6.0 mg/dL more often than ALLO treatment at commonly prescribed doses.

[1023] Rilonacept for Gout Flare Prevention: Subgroup Analysis of Patients Initiating or Continuing Uric Acid-Lowering Therapy in a Randomized, Placebo-Controlled Trial.

John S. Sundy1, H. Ralph Schumacher2, Roy M. Fleischmann3, Johannes M. Engelbrecht4, Steven P. Weinstein5, Jian Wang5, Shirletta King-Davis5 and Robert R. Evans5.
1Duke University Medical Center, Durham, NC, 2VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3MCRC, University of Texas, Dallas, TX, 4Vergelegan Medi-Clinic, West Cape, South Africa, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Conclusion: Weekly treatment with rilonacept 160mg resulted in similar efficacy in patients initiating or continuing uric acid-lowering therapy who were at risk of gout flares. Pre-filled syringes demonstrated efficacy similar to lyophilized drug in vials. Efficacy was also consistent in patients meeting the additional inclusion criteria from previous phase 3 studies. No new safety signals were observed.

[1025] Pharmacological Treatment of Acute Gout: A Systematic Review.

Puja Khanna1, Manjit K. Singh2, John D. FitzGerald3, Sangmee Bae2, Shraddha Prakash3, Marian Kaldas3, Maneesh Gogia3, Paul Maranian4, Robert Terkeltaub5 and Dinesh Khanna6.
1University of Michigan, Ann Harbor, MI, 2David Geffen School of Medicine at UCLA, Los Angeles, CA, 3UCLA, Los Angeles, CA, 4UCLA Medical School, Los Angeles, CA, 5VA Medical Ctr, San Diego, CA, 6University of Michigan, Ann Arbor, MI
Conclusion: NSAIDs and colchicine are effective in treating acute gout attack. Corticosteroid, ACTH, and canakinumamb can be used in patients who have contraindications to NSAIDs and colchicine.

[1027] Efficacy of Combined Treatment with Allopurinol and Benzbromarone in Gout Patients with Chronic Renal Impairment.
J
i Seon Oh1, Seung Won Choi1, Bon San Koo2, Min Wook So2, Yong-Gil Kim2, Chang-Keun Lee2 and Bin Yoo2.
1University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea, 2University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Conclusion: This study results suggest that combined treatment with allopurinol and benzbromarone may be an effective strategy for achieving the goal of uric acid levels in gout patients with moderate to severe renal impairment.

[1032] Uncontrolled Serum Uric Acid Is Associated with An Increased Risk of Developing Renal Disease In Veterans with Gout.

Eswar Krishnan1, Hari Sharma2, Bhavik J. Pandya3, Maryna Marynchenko2, Andrew Yu2, Eric Wu2, Jinan Liu4 and Lizheng Shi4.
1Stanford University, Stanford, CA, 2Analysis Group, Inc., Boston, MA, 3Takeda Pharmaceuticals International, Inc., Deerfield, IL, 4Tulane University, New Orleans, LA
Conclusion: Compared to controlled sUA levels, uncontrolled sUA levels are associated with increased risk of a new diagnosis of renal disease among veterans with gout.

[1033] Clinical Characteristics of Difficult-to-Treat Gout Patients: a Principal Components Analysis.

Elizaveta Vaysbrot1, Yoojin Lee1, Sarah McLaughlin1, Neetu Agashivala2, Anthony Yadao3, Timothy E. McAlindon1 and William F. Harvey1.
1Tufts Medical Center, Boston, MA, 2Novartis Pharmaceutical Corporation, East Hanover, NJ, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ
Conclusion: The four out of five factors had components with clinical relationships: cardiovascular diseases, gastrointestinal disorders, metabolic syndrome and features of advanced gout. The components in factor 4 did not have a clear clinical relationship. The study was limited by its retrospective nature, small sample size, and an inexact, exploratory nature of PCA method. Characteristics of this population may vary if using different definitions of difficult-to-treat. Despite the limitations, our results confirm the clinical intuition that the above conditions are linked to difficult-to-treat gout and may help design future research.

[1083] Presence of Gout Is Associated with Increased Osteoarthritis Prevalence and Severity.

Rennie N. G. Howard1, Jonathan Samuels1, Soterios Gyftopoulos1, Svetlana Krasnokutsky2, Joseph Leung3, Christopher Swearingen4 and Michael H. Pillinger1.
1NYU Langone Medical Center/NYU Hospital for Joint Diseases, New York, NY, 2NYU Hospital for Joint Disease, New York, NY, 3New York, NY, 4University of Arkansas for Medical Sciences, Little Rock, AR
Conclusion: Our data suggest that presence of gout puts subjects at significantly higher risk for increased knee OA prevalence and severity. AH may independently convey knee OA risk but our sample size was inadequate
for statistical confirmation. MSU crystal deposition as detected by US was also significantly higher in subjects with knee OA. Presence of gout or AH, as well as MSU crystal deposition on US, could potentially serve as useful biomarkers for knee OA risk, severity and progression. The possibility that gout and/or AH might contribute to OA risk suggests that UA management should be assessed as a potential intervention in OA patients.

[1599] Allopurinol Initiation and the Risk of Death in the General Population.

Yanyan Zhu1, Yuqing Zhang2, John D. Seeger3, Young Hee Rho4, Christine Peloquin1 and Hyon K. Choi1.
1Boston University School of Medicine, Boston, MA, 2Boston University Clinical Edpidemiology Reserach and Training Unit, Boston, MA, 3Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, 4Vanderbilt Medical Center, Nashville, TN
Conclusion: In this general population study, allopurinol initiation was associated with a modestly reduced risk of death. The overall benefits of allopurinol may outweigh its impact of rare, potentially serious adverse effects at a population level

[1602] Uncontrolled Serum Uric Acid In Veteran Gout Patients Is Associated with a Higher Risk of Diabetes.

Bhavik J. Pandya1, Maryna Marynchenko2, Hari Sharma2, Andrew Yu2, Eric Wu2, Lizheng Shi3, Jinan Liu3 and Eswar Krishnan4.
1Takeda Pharmaceuticals International, Inc., Deerfield, IL, 2Analysis Group, Inc., Boston, MA, 3Tulane University, New Orleans, LA, 4Stanford University, Stanford, CA
Conclusion: Among VISN 16 pts with gout, uncontrolled sUA was associated with a higher risk of a new diagnosis of diabetes when compared with controlled sUA.